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Abstract
Monkeypox viruses (MPXV) cause human monkeypox, a zoonotic smallpox-like disease endemic to Africa, and are of
worldwide public health and biodefense concern. Using viruses from the Congo (MPXV-2003-Congo-358) and West African
(MPXV-2003-USA-044) clades, we constructed recombinant viruses that express the luciferase gene (MPXV-Congo/Luc+and
MPXV-USA-Luc+) and compared their viral infection in mice by biophotonic imaging. BALB/c mice became infected by both
MPXV clades, but they recovered and cleared the infection within 10 days post-infection (PI). However, infection in severe
combined immune deficient (SCID) BALB/c mice resulted in 100% lethality. Intraperitoneal (IP) injection of both MPXV-
Congo and MPXV-Congo/Luc+resulted in a systemic clinical disease and the same mean time-to-death at 9 (60) days post-
infection. Likewise, IP injection of SCID-BALB/c mice with MPXV-USA or the MPXV-USA-Luc+, resulted in similar disease but
longer (P,0.05) mean time-to-death (1160 days) for both viruses compared to the Congo strains. Imaging studies in SCID
mice showed luminescence in the abdomen within 24 hours PI with subsequent spread elsewhere. Animals infected with
the MPXV-USA/Luc+had less intense luminescence in tissues than those inoculated with MPXV-Congo/Luc+, and systemic
spread of the MPXV-USA/Luc+virus occurred approximately two days later than the MPXV-Congo/Luc+. The ovary was an
important target for viral replication as evidenced by the high viral titers and immunohistochemistry. These studies
demonstrate the suitability of a mouse model and biophotonic imaging to compare the disease progression and tissue
tropism of MPX viruses.
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Introduction
Human monkeypox (MPX) is a zoonotic viral exanthema with
manifestations similar but less severe than smallpox [1]. The virus
(MPXV) belongs to the Orthopoxvirus genus of the Poxviridae family
and shares many biochemical and physical properties with other
orthopoxviruses, such as vaccinia and variola. MPXV is thought to
be maintained in wild rodents in the rain forests of Central and
West Africa, causing sporadic human outbreaks in remote villages
probably as a result of direct cutaneous contact or mucosal
exposure to infected animals [2–5]. Because the airborne route of
exposure is known to play a role in secondary human-to-human
transmission [6], concerns have been raised about the potential use
of MPX as a biological warfare agent and as such, the virus is
listed as a Category C select agent.
Monkeypox emerged for the first time in the Western
Hemisphere in 2003, causing an outbreak in the Midwestern
United States affecting 37 people that were exposed to ill prairie
dogs purchased from pet stores or through pet swaps [7–10]. The
virus entered the US upon the importation of exotic rodents from
Ghana (West Africa). Subsequent studies demonstrated the
existence of two genetically distinct variants of the virus, called
the West African and Congo Basin clades [11]. The strain that
caused the US outbreak belonged to the West African clade; which
is associated with less severe disease as compared to the Congo
Basin clade [12].
Several animal models have been used to study MPXV
pathogenesis, including newborn mice and rats [13], cynomolgus
monkeys [14,15], squirrels [16,17], prairie dogs [9,18], and
dormice [19]. Some of these studies were conducted using
conventional methods involving large sample size and sacrificing
animals to determine viral titers and histological changes. In the
present study, we describe the development of recombinant
MPXV expressing the luciferase gene (MPXV-USA-Luc+,
MPXV-Congo/Luc) and their use in monitoring disease progres-
sion in vivo with biophotonic imaging. This technique has been
used to study a variety of bacterial and viral infections [20–24].
Biophotonic imaging offers significant advantages over conven-
tional pathogenesis studies because it can: 1) be used to
quantitatively visualize viral infections in living animals; 2) allow
disease progression and outcome to be directly linked to virus
replication and virus load; 3) provide significant ethical advantages
because experiments can be carried out with fewer animals; 4)
result in faster data acquisition since images can be quantified
within minutes; and 5) reveal unsuspected sites of viral replication
and modes of viral spread.
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sion in both immunocompetent and immuno-compromised mice
between the West African and Congo clades via IP exposure. This
system could be used to address many questions about MPX
pathogenesis, including virulence factors, disease progression in
rodent hosts, and viral shedding from infected animals, an index of
the transmission potential to humans and other animals. In addition,
these tools can be used to test anti-virals and the next generation of
orthopoxvirus vaccines for their ability to alter the course of disease.
Results
Generation of recombinant virus and one-step growth
curves of MPXV
Sequencing and PCR analysis showed that recombinant
MPXV-USA-Luc+and MPXV-Congo-Luc+contained the lucifer-
ase gene inserted into the 176–177 intergenic regions. To
determine whether this insertion adversely affected the overall
growth characteristics of MPX viruses, we carried out one-step
growth experiments in Vero cell monolayers. Total virus
production, expressed as PFU/ml, was determined for samples
collected at various times after infection. For both wt and
Luc+viruses, the lag and rise period of exponential growth were
of similar duration, and gave comparable yields (Figure 1). Thus,
within experimental limitations, we concluded that the insertion of
the luciferase gene in our engineered viruses did not limit growth
in Vero cells.
Clinical presentation, morbidity, and mortality in mice
Several experiments were conducted to evaluate a mouse model
for MPXV infection. First, four-week-oldBALB/c mice (n=4)were
exposed to either wt or recombinant Luc+MPXV by the IP route
andmonitoredforclinical signs.Infected miceexhibited roughcoat,
inappetence, and decreased activity within 5 days and recovered by
approximately 10 days post-infection (dpi). A group of uninfected
controls (4 animals) did not develop any signs of disease.
In order to more fully characterize viral pathogenesis and
compare the virulence of the MPXV-USA-Luc+and MPXV-
Congo-Luc+strains with parental viruses, the next set of experiments
was conducted in 4-week-old immunocompromised SCID-BALB/c
mice. Groups of four SCID-BALB/c mice were IP inoculated with
10
5 plaque forming units (PFU)with either therecombinant MPXV-
USA-Luc+or MPXV-Congo-Luc+strains, the wild-type MPXV-
USA or MPXV-Congo strains, or diluent (n=2) and monitored for
clinical signs. Within 5 DPI, both MPXV-Congo and MPXV-
Congo/Luc+inoculated groups had evident signs of a systemic
clinical disease (rough coat, inappetence, decreased activity). All
mice in both groups died on the same day (day 9), indicating that
insertion of the Luc+gene did not result in viral attenuation.
InoculationofMPXV-USAandMPXV-USA/Luc+virusesinSCID
mice produced a similar disease, but clinical signs were not
observed until 7 DPI and all animals inoculated with both strains
died on the same day (day 11). The mean time-to-death of MPXV-
USA strains was significantly longer (P,0.05) than the MPXV-
Congo strains, indicating that the West African MPXV clade is less
pathogenic. Mice that received diluent remained healthy.
Visualization of MPXV infection
The MPXV-USA-Luc+and MPXV-Congo-Luc+strains were
used to monitor viral infection in vivo with biophotonic imaging.
Twenty-four hours after IP inoculation of the recombinant virus
and every day afterwards, SCID and immunocompetent BALB/c
mice were injected IP with luciferin and placed in the imager. In
BALB/c mice, luminescent signal was visualized as early as
24 hours PI (Figure 2). Infection with the MPXV-Congo-Luc+-
produced a more intense signal than MPXV-USA-Luc+, suggesting
stronger replication and faster spread. This signal peaked between
96-120 hours PI and was mostly limited to the organs in the
peritoneal cavity, with occasional spread to the axillary lymph
nodes. For both viruses, luminescent signal was undetectable by
240 hours, indicating that these animals had cleared the infection.
In SCID- BALB/c mice, luminescence indicative of MPXV
infection was also visible as early as 24 hours PI and limited at that
time to the peritoneal cavity (Figure 3). Once again, infection with
the MPXV-Congo-Luc+produced a more intense luminescent
signal, and by 96 hours PI, it had spread to other organs and
tissues in the abdominal region, the thoracic area, and axillary
lymph nodes. At 168 hours PI, luminescent signal was detected in
the entire body and animals died between 192 and 216 hours PI.
In SCID mice inoculated with MPXV-USA/Luc+, luminescent
signal was also visible in the abdominal region at 96 hours PI, and
it was visible in the tail, feet, and nasal area at 240 hours PI. All of
these animals died by 264 hours PI.
Virus titers from selected tissues and correlation with
luminescence
To monitor viral titers, tissues were aseptically harvested at the
time of death to compare viral titers between the parental viruses
and recombinant progeny Luc+strains and to correlate titers with
luminescence levels. No differences in viral titer were detected for
the Congo Luc+and wt strains for kidney (P=0.49), liver
(P=0.22), lung (P=0.25) and ovary (P=0.60). Likewise, no
differences in viral titer were detected between animals infected
with the USA/Luc+and wt strains (Figure 4) for kidney (P=0.41),
liver (P=0.75), lung (P=0.68), and ovary (P=0.89). These results
Figure 1. One-step growth curves for parental (MPXV-Congo,
MPXV-USA-2003) and progeny recombinant (MPXV-Congo-
Luc+, MPXV-USA-Luc+) viruses. Vero cell monolayers were infected
at multiplicity of infection (MOI) of 0.1 with parental (MPXV-Congo,
MPXV-USA-2003) or with progeny (MPXV-Congo-Luc+, MPXV-USA-Luc+)
strains. After allowing for attachment (30 min), cells were washed twice
with PBS to remove unattached virus. Then fresh medium as added and
plates were incubated at 37uC 5% CO2. At various intervals thereafter,
three wells per virus strain were harvested (media and cells) and placed
at 270uC. After three cycles of freezing and thawing, the samples were
sonicated and virus titers were determined by serial dilution and
infection of Vero cell monolayers. Plaques were visualized by staining
with 0.1% crystal violet in 20% ethanol and virus titers determined as
described elsewhere [39].
doi:10.1371/journal.pone.0006592.g001
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substantially alter virulence of the virus. Viral titers in the ovaries
were about 2 logs higher than in other tissues for both the Congo
and USA strains. Using data collected from kidney, liver and lung
extracts from both MPXV-Luc+strains, a correlation (Figure 5)
was detected between measured luminescence and viral titer
(R
2=54%; P=0.0008). Data from ovarian extracts were not
included in the analysis because viral titers were much higher than
the other tissues. With the resulting calibration curve generated,
approximate viral titer can be calculated in future studies using the
following formula: titer=38.587+0.0011 photons/s/ml.
Immunostaining of tissues derived from MPXV infected
animals
MPXV antigen was consistently detected in ovary, intestinal
muscle wall and skin of the feet sampled from SCID/BALB/c
mice inoculated IP with either parental (MPXV-Congo, MPXV-
USA-2003) or recombinant (MPXV-Congo-Luc+, MPXV-USA-
Luc+) viruses (Figure 6B, D, and F). In addition, small random
areas containing MPXV antigen were detected in lung, heart,
liver, kidney, and pancreas (data not shown). No MPXV antigen
was detected in any of the tissues sampled from uninfected SCID/
BALB/c mice (Figure 6A, C, and E). The amount of antigen
staining in the ovary was diffuse with intense antigen staining of
follicular tissue.
Histologic Findings
Consistent pathology was seen in the ovary, skin, and serosa of
intestine sampled from SCID BALB/c mice infected IP with wt
parental and recombinant MPXV-USA-2003 and MPXV-Congo
clades. The ovary was severely necrotic with loss of architecture
and subacute inflammation of surrounding tissues (Figure 7A). The
Figure 2. In vivo imaging of MPXV-Congo-Luc+ (left panel) and MPXV-USA-Luc+ (right panel) in BALB/c mice (Intraperitoneal
inoculation). Groups of four, 4-week-old BALB/c mice were inoculated by the IP route with 105 PFU of either MPXV-Congo-Luc+or MPXV-USA-
Luc+viruses. At indicated times post-infection, mice were injected IP with 1.5 mg luciferin in 100 ml of DPBS (Promega, Madison, WI) and imaged
(ventral view) in an IVIS 200 imager (Caliper Life Sciences, Alameda, CA). Exposures for 30 sec (F8, medium binning) were taken at approximately 12
minutes post-luciferin injection following anaesthetization with isoflurane. An uninfected negative control animal (first animal on left side) was also
injected with luciferin and imaged on the same times as infected animals. Images were analyzed with Living Image 3.0 software (Caliper Life Sciences,
Alameda, CA). A) 24 h; B) 96 h; C)168 h; D) 240 h.
doi:10.1371/journal.pone.0006592.g002
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macrophages and necrotic debris. Neutrophils, macrophages and
red blood cells were also present in the open space of the ovarian
bursa. The serosa of the intestine was mildly proliferative and
occasionally associated necrosis of underlying smooth muscle.
Multifocal lesions involving the skin of the feet and tail consisted of
hyperkeratosis, acanthosis and subacute deep dermal inflamma-
tion. Eosinophilic cytoplasmic inclusion bodies, suggesting viral
inclusions (Guarnieri bodies), were infrequently present in the
vacuolated epithelium of the stratum spinosum of the hyperker-
atotic skin (Fig. 6F). Intradermal bullae were filled with edema and
scattered necrotic debris (Figure 7B) with ballooning degeneration
of surrounding epithelium. Mild multifocal apoptosis was less
consistently seen in liver and pancreas (data not shown).
Discussion
By constructing recombinant MPX viruses that expresses the
luciferase gene (Luc+), we have characterized and compared the
progression of disease in mice infected with MPXV-Congo and
MPXV-USA strains. In addition, we established appropriate
animal models for further study of MPX viruses in general. We
found that 4-week-old immunocompetent BALB/c mice became
ill after IP exposure to either the Congo or USA viruses but
recovered fairly quickly from the infection. In contrast, 4-week-old
immunocompromised SCID-BALB/c mice were highly suscepti-
ble to MPXV, with infection resulting in 100% lethality for both
the Congo and USA viruses. Time-to-death in SCID BALB/c
mice following IP infection was similar for the parental wild type
(wt) and recombinant Luc+viruses for both the Congo and USA
strains, indicating that insertion of the Luc+gene did not result in
viral attenuation, but the Congo viruses have stronger replication
and faster spread confirming previous reports regarding the
increased virulence of this viral clade [25]. Our studies are the first
of this type to provide an extensive evaluation of MPXV infection
and disease progression in well defined mouse laboratory strains.
Although previous work reported MPXV infection in newborn
laboratory rats and mice [26], the genetic background of the
animals used in that study were not described.
The use of a recombinant MPX- Luc+viruses and biophotonic
imaging provided significant advantages over conventional
pathogenesis experiments involving tissue harvesting and titration
studies to determine MPX disease progression and its correlation
to virus replication/luminescence levels in the laboratory mouse
model. While the limit of detection by luminescence for our MPX-
Luc+viruses is unknown, previous studies with Sindbis virus have
Figure 3. In vivo imaging of MPXV-Congo-Luc+ (left panel) and MPXV-USA-Luc+ (right panel) in SCID- BALB/c mice (Intraperitoneal
inoculation). A group of four, 4-week-old SCID BALB/c mice was inoculated by the IP route with 105 PFU of MPXV-USA-Luc+virus and imaged as
described as described in materials and methods. An uninfected negative control animal (on left) was also injected with luciferin and imaged on the
same times as infected animals. Ventral view.
doi:10.1371/journal.pone.0006592.g003
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3 PFU/g [23]. Subsequent studies
will focus in the validation of in vivo imaging through serial sacrifice
studies and comparison of luminescence and viral levels in organs
throughout the disease course. Following IP inoculation of SCID
mice, luminescence-indicative of MPXV-Luc+replication-was
visible in the peritoneal cavity within 24 hours PI, and during
early stages, the infection for both viral clades was limited to
organs in the abdominal region. Infection with MPXV-Congo-
Luc+spread faster and by 96 hours was detected in lymph nodes in
the axilliary region, whereas for MPXV-USA-Luc+only later (day
7-10) was luminescent signal visible in the nasal area, tail and feet.
It is unclear whether spread to these areas occurred following
viremia facilitated by infected dendritic cells or through viral
shedding in feces or urine. For other poxviruses, such as
ectromelia, the skin is the primary site of viral infection [27].
In vivo imaging of SCID mice injected IP revealed a very high
tropism of MPXV for ovarian tissues. This result was confirmed by
the high viral titers (.10
5 PFU) measured in ovaries of infected
mice and IHC studies that showed ovaries had the most intense and
diffuse staining compared to other tissues. A previous study in non-
human primates also reported detection of MPXV antigen in
ovarian tissues [14], but it was not a primary site of viral replication.
The extent of viral spread in SCID BALB/c mice was affected by
the viral clade. Inoculation by the IP route of both viral clades
resultedinitiallyininfectionoforgansintheperitonealcavity.Then,
for MPXV-Congo-Luc+, infection resulted in a more disseminated
spread and luminescence signal was detected in the entire body.
While these studies provide new knowledge regarding the
pathogenesis of MPXV in the laboratory mouse, the relevance of
this model when compared to human monkeypox disease and non-
human primate model remainsto be seen.FollowingIP inoculation,
micedeveloped asystemicdiseaseandviruswasdetected inmultiple
organs, including lungs, kidneys and ovaries. Furthermore, in vivo
imaging showed significant viral replication in the skin (tail, feet),
producing multiple well-defined pustule lesions with the presence of
Guarneri inclusion bodies as confirmed by histology and immun-
histochemistry. However, no clinical signs of rash were observed in
infected animals,suggesting that thismodelmight not becompletely
comparable to human monkeypox disease. The IP route of
inoculation was used in this initial study in order to provide a
highly consistent dose of virus to establish imaging procedures.
Parenteral routes of infection (intravenous, subcutaneous, intraper-
itoneal, footpad) have been used by others to establish MPXV
animal models in non-human primates, squirrels, prairie dogs and
dormice [16,18,28,29]. In future studies, the intranasal route will be
used since this route simulates natural infection with MPXV.
The marked difference in pathogenesis observed between SCID
mice and immune-competent BALB/c mice provides an opportu-
nity to investigate the immune responses that protect against
MPXV infection. Because luminescence in the immunocompetent
BALB/c mice peaked at 96 hours post-infection, early events in the
host immune response are probably important in controlling
MPXV infection. While SCID mice lack of T or B cell responses,
they can fully mount innate (e.g cytokines) immune responses. In
subsequent studies we will compare these innate responses between
immunocompetent and SCID BALB/c mice in an attempt to
elucidate their role in MPXV infection. Studies with vaccinia have
demonstrated the importance of interferon in viral spread and
pathogenesis since IN infection in mice lacking receptors for type I
interferons (IFN I R 2/2) resulted in more systemic spread into
abdominalorgans[30].Thereislittleconsensus atthe presentabout
the correlates of protection in animals infected with MPXVor other
related poxviruses. Most of the understanding of the host response
to poxvirus infection in humans comes from historical clinical data
collected from smallpox patients and vaccinated individuals.
Cytotoxic T lymphocytes (CTL) and antibody responses are
associated with virus control in vaccinia-vaccinated individuals
and those who have previously recovered from smallpox [31].
Patients with abnormalitiesin T-cell function developedgeneralized
vaccinia, whereas patients with congenital agammaglobulinemia
did not [32]. There is also a growing appreciation of the importance
of antibody in virus control and animal recovery in other models of
both primary and secondary poxvirus infections. In macaques,
vaccinia vaccination induced protection against a lethal intravenous
challenge with MPXV [33]. Animals depleted of B cells were
susceptible to infection, but not if they were depleted of either CD4
or CD8 T cells [34].
Figure 4. Virus titers from selected tissues and correlation with
luminescence. Tissues samples from kidney, liver, lung and ovaries
were aseptically harvested to compare viral titers between the parental
MPXV-USA-2003 and recombinant progeny MPXV-USA-Luc+strains.
Tissue homogenates were centrifuged as described in materials and
methods section. Viral titers were calculated per gram of tissue.
doi:10.1371/journal.pone.0006592.g004
Figure 5. Correlation between viral titers with luminescence
levels. The luminescence of kidney, liver, and lung tissue lysates was
measured with the IVIS imager. A calibration curve was then generated
using inverse regression analysis and plotting virus titer (PFU/g) against
luminescence (photons/sec). MPXV-USA-2003-Luc+(N). MPXV-Congo-
Luc+(#).
doi:10.1371/journal.pone.0006592.g005
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these luciferase-expressing viruses in combination with in vivo
animal models can also provide important tools in the
development of novel anti-orthopoxvirus therapeutics. Similar
studies have been conducted using luminescent herpes simplex
virustype1(HSV-1)[21].Noantiviraldrughasbeenproventobe
effective in the treatment of human smallpox. The only antiviral
agent currently approved for use against orthopoxviruses is
cidofovir [35]. However, this compound has low oral bioavail-
ability and must be administered intravenously, limiting its
usefulness.
The recombinant MPXV-Luc+viruses we constructed appear to
be highly stable and fully virulent. After sequence analyses, we
selected several MPXV intergenic regions, including 141–142 and
176–177, as the sites for Luc+insertion. The primary factors
involved in the selection of these regions included the lack of
potential promoter sequences and also sufficient distance from
nearby genes, thus decreasing the chance of functional disruption
by the foreign gene insertion. Although we initially inserted the
luciferase gene into the 141–142 region, the resulting virus had
reduced virulence compared to the parental virus in SCID mice
(data not shown). The recombinant MPXV-Luc+used in this study
was created using the 176–177 intergenic region. Following five
rounds of plaque purification, and pathogenesis studies in 12
animals, the luciferase insert was still present in the recombinant
viruses as shown by luminescence and sequence data, indicating
that the MPXV-Luc+were stable and the 176–177 intergenic
region can efficiently maintain the foreign gene. In addition, in vitro
experiments, such as one-step growth curves, and in vivo virulence
studies in mice showed that recombinant Luc+viruses maintained
the phenotypic and virulence properties of the parental viruses.
Another advantage of the Luc+insertion is the ability to use the
marker to quantify virus in animal tissues. We found a strong
correlation between luminescence in tissue extracts from infected
mice and viral titers quantified by traditional plaque assays. This
finding can be used in future studies for faster quantification of
Figure 6. Immuno-histochemical staining in tissues of mice infected with MPXV. Tissues from 4-wk-old SCID/BALB/c mice infected IP with
MPXV-USA-2003-Luc+and uninfected SCID/BALB/c mice were stained by using vaccinia mouse hyperimmune mouse and horse-radish peroxidase as a
detection label. MPXV antigen was identified in the intestine, ovary and skin of the feet (7B, D, and F respectively). Poxviral inclusions were seen in the
skin of a foot (7F arrows). MPXV antigen was also found in the nasal turbinate of IN infected mice (7H). None of the IHC-stained tissues of the control
mice including intestine, ovary, and skin (7A, C, and E respectively) had viral antigen staining.
doi:10.1371/journal.pone.0006592.g006
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harvesting and processing tissues for viral titration, particularly
for select agents such as MPXV. Unfortunately, quantification of
virus using this method is not as sensitive as plaque assays and
molecular techniques (real time PCR). However, the ability to
monitor animals longitudinally compensates for the loss in
sensitivity compared to that of the plaque assay and adds the
dimension of time to disease progression and pathogenicity studies.
In summary, we have constructed highly stable recombinant
MPXV- Luc+viruses that can be used in biophotonic imaging
studies to provide further insight into MPXV pathogenesis and
host response to infection. The availability of these viruses also
provide a unique opportunity to study MPXV infection in known
wild rodent hosts from Africa as well as prairie dogs and other U.S.
rodents that could serve as hosts of the virus if subsequent
introductions of the virus occur. In future studies, we will use
luciferase-expressing viruses to study pathogenesis via IN and
other routes of infection and to better assess the role of specific
genes in the pathogenesis of MPXV. A recent study suggested that
several genes, including D10L, D14L, B10R, B14R and B19R
might play an important role in MPXV virulence [12].
Understanding the factors that increase MPXV virulence can
aid the development of vaccines and anti-virals that could be used
to prevent or treat human monkeypox.
Materials and Methods
Viruses and cells
MPXV-USA (Strain designation 044) was kindly provided by Dr.
Inger K. Damon. (CDC, Atlanta, GA).This virus was isolated during
the USA outbreak in 2003 [10]. MPXV-Congo was isolated during a
2003 outbreak of MPX in the Republic of Congo (ROC) and
designated as MPXV-2003-358. Recombinant viruses were gener-
ated and amplified on cell monolayers of rat embryonic fibroblasts
(Rat-2, CRL-1764) or African green monkey kidney epithelial cells
(BSC-1: CCL-26; or Vero: CCL-18) obtained from American Type
Culture Collection (ATCC), Manassas, VA. Cell cultures were
maintained at 37uCa n d5 %C O 2in Medium 199 supplemented with
0.01 g/L L-glutamine and 5% fetal bovine serum (FBS).
Construction of pGPT/luc/PCSII recombinant plasmid
vector
We used the guanine phosphoribosyl transferase (GPT) gene as
a selection system to generate recombinant MPXV containing the
luciferase (Luc+) marker. For this purpose, we constructed a
plasmid (pGPT/luc/PCSII) containing the GPT and Luc+genes
under the control of the synthetic early late promoter (SE/L). This
plasmid also contains MPXV sequences to allow cloning into the
176–177 intergenic regions for both MPXV-Congo and MPXV-
USA clades.
Construction of a MPXV transfer vector with polycloning
sites
P l a s m i dp U C 1 8w a sd i g e s t e dw i t hPvu II and gel-purified to
remove the LacZ and polycloning site sequences. This plasmid
contributed the backbone for the MPX transfer vector. Then, two
oligonucleotides (59-GGCCGGCCGGACCGACACCCTAGGAC-
TAGTCGATGCTAGCGCCAGGCGCGCCGGGCCC-39 and
59-GGGCCCGGCGCGCCTGGCGCTAGCATCGACTAGTC-
CTAGGGTGTCGGTCCGGCCGGCC-39) were synthesized and
annealed to form a double stranded molecule containing multiple
cloning sites. For this purpose, 2 mg of each oligonucleotide were
resuspended in 100 ml of 50 mM Tris pH 8.0, and incubated at 72uC
for 10 min. The mixture was then allowed to slowly cool to room
temperature. Ten microliters of the annealed mixture were employed
in a blunt-end ligation reaction (room temperature, overnight) with
the Pvu II-digested pUC18plasmid. Theresultingplasmid, designated
pPCSII, was sequenced and then purified for further manipulation
(Figure 8A).
Cloning of the GPT gene under poxvirus promoter
control
Plasmid pSV2-GPT (ATCC #37145) was used to clone the GPT
gene. Primers for GPT amplification were 59-CGTACA-
TAAGCTTTGGGACACTTCACATGAGCG-39 containing a
Hind III site (bold italicized) and 59-GTGATCTAGAGAC-
GACGGTCACTAGTGGAAACTATTGTAACCCGCC-39 con-
taining an Xba I site. The two restriction enzyme recognition sites
were included to facilitate subsequent cloning procedures. Ampli-
fication was carried out for 35 cycles at 94uC for 30 sec, 50uC for
15 sec and 72uC for 2 minutes. The amplification product was
purified by passage through a Qiaquick PCR purification column
(Qiagen Sciences, Valencia, CA), digested with Hind III and Xba I
restriction enzymes at 37uC for 3 hr, and purified by another
passage through a Qiagen PCR purification column. The purified
fragment was then cloned into the pTK/Sel2 plasmid [36] that had
been previously digested with Hind III and Xba I. This plasmid,
Figure 7. Histological sections from mice infected with MPXV-USA-2003 stained with hematoxylin and eosin. A) Necrosis of ovarian
follicles (arrow) with subacute inflammation infiltrating surrounding connective tissue and peri-ovarian fat. B) Skin of foot with intradermal bulla
containing edema and cell debris (arrow). Surrounding epidermis is undergoing ballooning degeneration.
doi:10.1371/journal.pone.0006592.g007
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from a poxvirus synthetic early/late promoter (SE/L).
Construction of the MPXV transfer vector containing the
GPT gene
The pTK-GPT plasmid was digested with restriction enzymes
Asc I and Nhe I to excise the SE/L- GPT fragment. Simultaneous-
ly, the pPCSII plasmid was digested with Asc I and Spe I enzymes.
Spe I generates identical overhanging ends as Nhe I and facilitates
ligation of the Nhe I/Asc I fragment containing GPT into the vector
with destruction of both Spe I and Xba I restriction enzyme sites.
The resulting product was purified through a Qiaquick column
and ligated to the GPT/SE/L fragment to generate the pGPT/
PCSII plasmid (Figure 8C).
Cloning of the luciferase gene under poxvirus control
To generate a luciferase gene under the control of a poxvirus
promoter, we first digested plasmid pTK/Sel2 with restriction
enzymes Xba I and Hind III which was purified through a Qiaquick
PCR purification column. To obtain the luciferase gene, plasmid
pGL3 (Promega, Madison WI) was also digested with Xba I and
Hind III enzymes and the lucifierase-containing DNA fragment
was purified from an agarose gel. The fragment and vector were
ligated to form plasmid pTK/Sel2/luc (Figure 8D).
Figure 8. Construction of MPXV-Luc+viruses. A) Two synthetic DNA fragments containing the p7.5 promoter from vaccinia were annealed and
cloned into the pUC18 plasmid, resulting into the pPCSII, plasmid. B) The GPT gene was PCR amplified and cloned into the pTK/Sel2 plasmid resulting
in the pTK-GPT plasmid. C) The SE/L-GPT fragment was removed from the pTK-GPT plasmid and ligated into the pPCSII plasmid generating the pGPT/
PCSII plasmid. D) The luciferase gene was cloned into the plasmid pTK/Sel2/luc plasmid. E) The SE/L-luciferase fragment was cloned into the pGPT/
PCSII plasmid to generate pGPT/luc/PCSII construct. Then, MPXV regions, sequences for the left (176L) and right (176R) flanking sequences of the
intergenic region 176–177 were cloned into the pGPT/luc/PCSII. The resulting plasmid was then used to generate recombinant MPXV.
doi:10.1371/journal.pone.0006592.g008
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The pTK/Sel2/luc plasmid was digested with Spe I and Bam HI
and the SE/L-luciferase fragment was extracted from an agarose
gel and purified as described above. Simultaneously, the plasmid,
pGPT/PCSII was digested with Bam HI and Avr II and gel
purified. Enzyme Avr II contains overhanging ends that are
compatible with Spe I which facilitated the ligation of the SE/L-
luciferase fragment into the pGPT/PCSII plasmid to generate
pGPT/luc/PCSII construct.
To target the integration of the two GPT and Luc+genes into
specific MPXV regions, sequences for the left flanking sequence
(176L) of the intergenic region 176–177 from MPXV-USA-2003
strain were PCR amplified using primers 59CCGGCGCATATG-
GACTTACATAAATATCTGGGA 39 and 59AATTCGGCCG-
GACCGATACGATTATTAATAGCCG-39. The resulting PCR
product was digested with Nde I/Eag I and the 316 base pair (bp)-
fragment was cloned into the pGPT/luc/PCSII. The right
flanking sequence (176R) was also PCR amplified using primers
59 GCCGCTCGAGGCGATGGATTTAAACATC 39 and 59
TTAAGGCGCGCCGTTAAAATACATTCTAATACGG 39 and
the cDNA product was digested with Xho I/Asc I generating a
297 bp fragment that was then cloned into the pGPT/luc/PCSII.
The resulting plasmid was then used to generate recombinant
MPXV (Figure 8E).
Generation of recombinant MPXV viruses
Propagation of recombinant poxviruses using GPT selection
method was performed as described [37]. Briefly, BSC-1 cells at
80% confluence were infected at a multiplicity of infection (MOI)
of 0.06 with wt MPXV and then transfected with 4 mg of plasmid
DNA mixed with10 mL of Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) per well of a 6-well plate, according to
manufacturer’s instructions. Cells were then grown in medium
containing 25 mg/ml mycophenolic acid (MPA), 250 mg/ml
xanthine and 15 mg/ml hypoxanthine. MPA blocks the conversion
of inosine monophosphate (IMP) to guanine monophosphate
(GMP) affecting viral replication. The GPT enzyme is capable of
circumventing this block if hypoxanthine and xanthine are
present. Thus, only recombinant virus that contains the GPT
gene (and Luc+) will form plaques. Recombinant viruses were
plaque purified five times and assayed for luminescence in an IVIS
imager (Caliper Life Sciences, Almeda, CA) in the presence of
luciferin substrate (D-luciferin, Promega, Madison, WI).
One-step growth curve
To determine whether the insertion of the luciferase gene into
the intergenic regions affected the in vitro growth and other
phenotypic characteristics of MPXV, we conducted one-step-
growth studies using the MPXV-USA-2003, MPXV-USA-Luc+,
MPXV-Congo, and MPXV-Congo-Luc+strains. Vero cells
0.5610
6/ml per well) were seeded in a 6-well plate and incubated
overnight at 37C 5% CO2. Cell monolayers were infected with
MPXV at a multiplicity of infection (MOI) 0.1 for 30 min and
then washed twice with PBS and MEM media was placed onto the
wells. At 0, 4, 12, 24, 48, 72, and 96 hours post-infection, three
wells per virus strain were harvested (media and cells) by scraping
and placed at 280uC. After three cycles of freezing and thawing,
the samples were sonicated for three 20-second (sec) bursts of
75 W of output using a sonicator model W220 (Heat Systems
Ultrasonics, Inc., Farmingdale, N.Y.) [38], and virus titers
determined by serial dilution plaque assay on Vero cells. Plaques
were visualized by staining with 0.1% crystal violet and virus titers
determined as described elsewhere [39].
Animal studies
All animal studies were conducted in the BSL-3 animal facility
at the USGS-National Wildlife Health Center (NWHC, Madison,
WI) and approved by the NWHC Institutional Animal Care and
Use Committee (IACUC). Animal model development studies
were conducted using 3-to 4 week-old female BALB/c and BALB/
cJHanHad-Prkdc-SCID mice obtained from Harlan Sprague
Dawley, (Indianapolis, IN). Groups of animals were inoculated
by the intraperitoneal (IP, dose: 100 ml)) route, using either
parental (MPXV-2003-USA-044, MPXV-Congo-Luc+), recombi-
nant (MPXV-USA-Luc+, MPXV-Congo-Luc+) viruses, or PBS-
control. Following viral infection, all animals were monitored
twice a day for clinical signs and death. At different times post-
infection mice were injected IP with 1.5 mg luciferin in 100 mlo f
DPBS (Promega, Madison, WI) and imaged in an IVIS 200
imager. Exposures for 30 sec (F8, medium binning) were taken at
approximately 12 minutes post-luciferin injection following
anaesthetization with isoflurane. An uninfected control animal
was injected with luciferin and imaged simultaneously with
infected animals. Images were analyzed with Living Image 3.0
software (Caliper Life Sciences, Alameda, CA). If death occurred
or euthanasia was necessary to avoid animal suffering, tissue
samples from spleen, liver, kidneys, intestines, ovaries, lung, heart,
brain, and skin were aseptically collected and used for either
measurement of virus titer (snap frozen at -70uC) or fixed in a 10%
neutral buffered formalin solution.
Immunohistochemistry and Histopathology
To determine whether biophotonic imaging correlated with the
distribution of MPX viral antigen, immunohistochemistry (IHC)
was used to detect MPXV antigen in tissue sections. At necropsy,
brain, liver, kidney, heart, lung, intestine, adrenal glands, ovary
and skin of the feet were collected from SCID/BALB/c mice
infected with MPXV-USA-2003, MPXV-USA-Luc+, and from
uninfected control SCID/BALB/c mice. These tissues were
immediately fixed in 10% neutral buffered formalin. Tissues were
sectioned at 5 m and stained following standard IHC procedures
using a vaccinia mouse hyperimmune ascitic fluid (1:100 dilution,
kindly provided by Dr. R. Tesh University of Texas Medical
Branch, Galveston, TX) and HRP-conjugated anti-mouse IgG
(Abcam, Cambridge, MA) as a detection label [18]. Tissue sections
were also stained by the hematoxylin and eosin method.
Titration of virus from mouse tissue samples
Tissues were weighed and homogenized in 500 ml of 1 mM Tris
pH 9.0 in a pellet pestle homogenizer (Fisher Scientific, Pitts-
burgh, PA) followed by passage through a motorized Tissue
Tearor (Biospec Products, Bartlesville, OK) for 15 sec. Between
each tissue sample the homogenizer tip was sequentially
submerged in 2% Bacdown viracide for 10 sec, 10% chlorox,
70% ethanol, and distilled water twice and then blotted dry. The
homogenates were cleared by a 5 min centrifugation @ 60006gi n
a tabletop centrifuge. For determination of virus titer, serial
dilutions of each sample were made by mixing 45 ml of lysate in
405 ml of M199 media. Tubes were vortexed and four-fold serial
dilutions prepared. Each dilution (100 ml) was plated in triplicate
on a 48-well plate of 85% confluent Vero cells. The infection was
incubated at 37uC for 5 hours followed by removal of the infection
mixture and replacement with fresh M199 media. Plates were
incubated four days and then stained with 5% crystal violet in 20%
ethanol. Titer was calculated per gram of tissue and was compared
between the wild type and Luc+ strain for each tissue using a t-test
for unequal variances [40].
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Tissue luminescence was quantified using the IVIS 2000 imager
to develop a correlation curve between virus titer and lumines-
cence for use in future studies to approximate virus titer. Briefly,
tissue lysates (20 ml of 1:10 v/v for kidney, liver, and lung; 1:100
v/v for ovary) were added to an opaque black 96-well plate in
triplicate (Fisher Scientific, Pittsburgh, PA), and incubated with
70 ml of a mixture containing 15 mg/ml luciferase substrate in
sterile DPBS (Caliper Life Sciences, Hopkinton, MA), and the
luminescence measured with the IVIS imager. Exposure time was
adjusted to 30 sec to obtain the maximum unsaturated signal. A
calibration curve was then generated using inverse regression
analysis and plotting virus titer (PFU/g) against luminescence
(photons/sec).
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